Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy After Left Atrial Appendage Closure With the LAmbre Device in Patients With Nonvalvular Atrial Fibrillation: A Multinational Real-world Registry

NCT ID: NCT06620757

Last Updated: 2025-07-04

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 234 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-10-10
• Study Completion Date: 2027-10-01

Brief Summary

Brief Summary: A prospective, multicenter, single-arm, non-randomized study including consecutive patients with nonvalvular AF(Atrial Fibrillation), with a CHA2DS2-VASc score ≥2 (men) or ≥3 (women), and contraindication for long-term anticoagulant treatment, with successful LAAC (Left Atrial Appendage Closure)procedure with the LAmbre device, who at discharge are eligible for short-term (3-months-only) SAPT. We want to assess if a short-term single antiplatelet therapeutic regime of Acetylsalicylic acid (ASA) 100 mg (or clopidogrel 75 mg if ASA contraindication), once daily, for 3 months is safe and effective at 12 months follow-up.

Detailed Description

The S-SAPT SECURE-LAMBRE REGISTRY is a prospective, multicenter, single-arm, non-randomized study including consecutive patients with nonvalvular AF, with a CHA2DS2-VASc score ≥2 (men) or ≥3 (women), and contraindication for long-term anticoagulant treatment, with successful LAAC procedure with the LAmbre device, who at discharge are eligible for short-term (3-months-only) SAPT.

234 patients will be enrolled in the study. The study will be conducted at about 20 investigational centers in Spain. The enrollment phase is expected to take approximately 18 months.

Patients included in the study will be clinically followed for 12 months. In addition patients will have imaging (TEE or cCT) follow-up at 45-90 days and 12 month.

The hypothesis of the study is the following: After successful procedure of implantation of the Lifetech LAmbre Left Atrial Appendage Closure (LAAC) device in patients with nonvalvular paroxysmal, persistent, or permanent Atrial Fibrillation (AF), a short-term single antiplatelet therapeutic regime of Acetylsalicylic acid (ASA) 100 mg (or clopidogrel 75 mg if ASA contraindication), once daily, for 3 months is safe and effective at 12 months follow-up.

Objectives:

Primary objective. To evaluate the occurrence of stroke and thromboembolic events at 12 months with short-term SAPT with ASA 100 mg (or clopidogrel 75 mg if ASA contraindication) once daily during 3 months after successful LAAC with the LAmbre device.

Secondary objective. To evaluate the occurrence of major bleeding events at 12 months with short-term SAPT with ASA 100 mg (or clopidogrel 75 mg if ASA contraindication) during 3 months after successful LAAC with the LAmbre device.

Endpoints:

Primary endpoint. A composite of stroke (including ischemic and/or hemorrhagic) and/or systemic embolism at 12 months.

Secondary endpoints.

1. Device thrombosis at 45-90 days, if suggested by Transesophageal Echocardiography (TEE), confirmed by a cardiac Computed Tomography (cCT) scan.

2. Device thrombosis at 1 year, if suggested by TEE, confirmed by a CT scan.

3. Cardiovascular death at 12 months.

4. Nonprocedural major bleeding events (Bleeding Research Academy Consortium [BARC] ≥3b) at 12 months.

5. The composite of cardiovascular death, stroke, systemic embolism, and nonprocedural bleeding at 12 months.

6. All-cause death at 12 months. This study has an steering Committee, an independent Data and Safety Monitoring Board (DSMB) and independent Clinical Events Committee (CEC).

Conditions

Atrial Fibrillation

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

Single Antiplatelet therapy after Left Atrial Appendage Occlusion (LAAO)

Single antiplatelet therapy (SAPT)

Intervention Type: DRUG

Observational study of effectiveness and safety of SAPT (either with acetyl-salycilic acid or clopidogrel) after LAAO with Lambre device in patients with high risk of bleeding

Interventions

Single antiplatelet therapy (SAPT)

Observational study of effectiveness and safety of SAPT (either with acetyl-salycilic acid or clopidogrel) after LAAO with Lambre device in patients with high risk of bleeding

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

All criteria must be met

• Patient 18 years and over and
• Patient with documented nonvalvular AF, defined as AF in the absence of moderate or severe mitral stenosis or a mechanical heart valve and
• Patient with a calculated CHA₂DS₂-VASc score ≥2 (for men) and ≥3 (for women) and
• Patient with a contraindication for long-term anticoagulant treatment and
• Patient who has undergone a successful LAmbre LAAC device implantation with no complications during the in-hospital period after the intervention and
• Patient able and willing to return for required follow-up visits and examinations and
• Patient with Informed consent signed.

Exclusion Criteria

• Patient is currently enrolled in another investigational study, except when the subject is participating in a purely observational registry with no associated treatments.
• Patient requires long-term anticoagulation therapy for reasons other than AFrelated stroke risk reduction, for example, due to an underlying hypercoagulable state (i.e even if the device is implanted, the subjects would not be eligible to discontinue OAC (Oral Anticoagulation) due to other medical conditions requiring chronic OAC therapy).
• Patient has contraindications or is allergic to both aspirin and clopidogrel.
• Patient has an indication for chronic aspirin or clopidogrel treatment (i.e., chronic ischemic disease or peripheral artery disease); thus, the subject would not be eligible to discontinue aspirin or clopidogrel due to other medical conditions requiring this therapy.
• Patient had or is planning to have any cardiac or noncardiac intervention or surgical procedure within 30 days before or 60 days after implant (including, but not limited to: cardioversion, PCI (Percutaneous Coronary Intervention), cardiac ablation, cataract surgery, etc.).
• Patient had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 30 days prior to enrollment.
• Patient had a major bleeding event within the 30 days prior to inclusion. Lack of resolution of related clinical sequelae or planned and pending interventions to resolve bleeding/bleeding source are further exclusions, regardless of the timing of the bleeding event.
• Patient has an active bleeding.
• Patient has had an MI documented in the clinical record as either a NSTEMI or STEMI, with or without intervention, within 30 days prior to enrollment.
• Patient has a history of atrial septal repair or has an ASD/PFO device.
• Patient is of childbearing potential, or plans to become pregnant during the study (method of assessment upon study physician's discretion).
• Patient had subject has a documented life expectancy of less than one year.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fundación EPIC

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hospital Universitario A Coruña

A Coruña, , Spain

Site Status: RECRUITING

Hospital Clínico San Carlos

Aravaca, , Spain

Site Status: RECRUITING

Hospital Del Mar

Barcelona, , Spain

Site Status: RECRUITING

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status: RECRUITING

Hospital Universitari Vall D'Hebron

Barcelona, , Spain

Site Status: RECRUITING

Hospital Clinic de Barcelona

Barcelona, , Spain

Site Status: RECRUITING

Hospital Universitario Reina Sofía de Córdoba

Córdoba, , Spain

Site Status: RECRUITING

Hospital Universitario La Paz

Fuencarral-El Pardo, , Spain

Site Status: RECRUITING

Hospital Universitario de Cabueñes

Gijón, , Spain

Site Status: RECRUITING

Hospital Universitario de Bellvitge

L'Hospitalet de Llobregat, , Spain

Site Status: RECRUITING

Hospital Universitario de Gran Canaria Doctor Negrín

Las Palmas de Gran Canaria, , Spain

Site Status: RECRUITING

Hospital Universitario de Leon

León, , Spain

Site Status: RECRUITING

Hospital Universitari Arnau de Vilanova

Lleida, , Spain

Site Status: RECRUITING

Hospital Central de La Defensa Gómez Ulla

Madrid, , Spain

Site Status: RECRUITING

Hospital Universitario Puerta De Hierro

Majadahonda, , Spain

Site Status: RECRUITING

Hospital de Manises

Manises, , Spain

Site Status: RECRUITING

Hospital Regional Universitario de Málaga

Málaga, , Spain

Site Status: RECRUITING

Hospital Universitario Son Espases

Palma de Mallorca, , Spain

Site Status: RECRUITING

Hospital Clínico Universitario de Salamanca

Salamanca, , Spain

Site Status: RECRUITING

Hospital Universitario Virgen del Rocío

Seville, , Spain

Site Status: RECRUITING

Hospital Universitario de Tarragona Juan XXIII

Tarragona, , Spain

Site Status: RECRUITING

Hospital Universitario y Politécnico La Fe

Valencia, , Spain

Site Status: RECRUITING

Countries

Spain

Central Contacts

BEATRIZ VAQUERIZO, MD, PhD

Role: CONTACT

bvaquerizo@psmar.cat

0034987876135

FUNDACION EPIC

Role: CONTACT

iepic@fundacionepic.org

34987876135

References

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. No abstract available.

Reference Type: BACKGROUND

PMID: 32860505 (View on PubMed)

Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013 Sep;34(35):2746-51. doi: 10.1093/eurheartj/eht280. Epub 2013 Jul 30.

Reference Type: BACKGROUND

PMID: 23900699 (View on PubMed)

Michaud GF, Stevenson WG. Atrial Fibrillation. N Engl J Med. 2021 Jan 28;384(4):353-361. doi: 10.1056/NEJMcp2023658. No abstract available.

Reference Type: BACKGROUND

PMID: 33503344 (View on PubMed)

Alkhouli M, Ellis CR, Daniels M, Coylewright M, Nielsen-Kudsk JE, Holmes DR. Left Atrial Appendage Occlusion: Current Advances and Remaining Challenges. JACC Adv. 2022 Nov 16;1(5):100136. doi: 10.1016/j.jacadv.2022.100136. eCollection 2022 Dec.

Reference Type: BACKGROUND

PMID: 38939465 (View on PubMed)

Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. Europace 2022; 24(1): 71-164.

Reference Type: BACKGROUND

Freeman JV, Higgins AY, Wang Y, Du C, Friedman DJ, Daimee UA, Minges KE, Pereira L, Goldsweig AM, Price MJ, Reddy VY, Gibson D, Doshi SK, Varosy PD, Masoudi FA, Curtis JP. Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2022 May 10;79(18):1785-1798. doi: 10.1016/j.jacc.2022.02.047.

Reference Type: BACKGROUND

PMID: 35512858 (View on PubMed)

Carvalho PEP, Gewehr DM, Miyawaki IA, Nogueira A, Felix N, Garot P, Darmon A, Mazzone P, Preda A, Nascimento BR, Kubrusly LF, Cardoso R. Network Meta-Analysis of Initial Antithrombotic Regimens After Left Atrial Appendage Occlusion. J Am Coll Cardiol. 2023 Oct 31;82(18):1765-1773. doi: 10.1016/j.jacc.2023.08.010. Epub 2023 Aug 21.

Reference Type: BACKGROUND

PMID: 37611779 (View on PubMed)

Korsholm K, Nielsen KM, Jensen JM, Jensen HK, Andersen G, Nielsen-Kudsk JE. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. EuroIntervention. 2017 Apr 20;12(17):2075-2082. doi: 10.4244/EIJ-D-16-00726.

Reference Type: BACKGROUND

PMID: 27973336 (View on PubMed)

Park JW, Sievert H, Kleinecke C, Vaskelyte L, Schnupp S, Sievert K, Lam YY, Stahli BE, Zhang D, Li A, Brachmann J. Left atrial appendage occlusion with lambre in atrial fibrillation: Initial European experience. Int J Cardiol. 2018 Aug 15;265:97-102. doi: 10.1016/j.ijcard.2018.02.120.

Reference Type: BACKGROUND

PMID: 29885707 (View on PubMed)

Llagostera-Martin M, Cainzos M, Salvatella N, Cubero-Gallego H, Mas-Stachurska A, Sanchez-Carpintero A, Tizon-Marcos H, Calvo-Fernandez A, Molina L, Vaquerizo B. Single antiplatelet therapy after left atrial appendage closure in patients with AF: safety and effectiveness. Rev Esp Cardiol (Engl Ed). 2024 Feb;77(2):150-157. doi: 10.1016/j.rec.2023.06.020. Epub 2023 Oct 23. English, Spanish.

Reference Type: BACKGROUND

PMID: 37879431 (View on PubMed)

Other Identifiers

EPIC39-S-SAPT LAMBRE

Identifier Type: -

Identifier Source: org_study_id